抗Pgp抗体PHMA02在肿瘤临床中的应用研究及预后分析

• 作 者: 许元富 杨纯正 熊冬生 邵晓枫 王珊 孙云晖 薛艳萍 李维廉
• 机 构: 中国医学科学院中国协和医科大学血液学研究所实验血液学国家重点实验室!天津市300020,中国医学科学院中国协和医科大学血液学研究所实验血液学国家重点实验室!天津市300020,中国医学科学院中国协和医
• 出 处: 中国肿瘤临床
• 发表日期: 1999年09期
• 关键词: PHMA02 Pgp 急性白血病 药敏实验 单克隆抗体 P-糖蛋白 多药耐药 实体瘤 淋巴结转移灶 临床符合率

目的：应用单抗ＰＨＭＡ０２ 对１４８ 例肿瘤患者Ｐ－ 糖蛋白（Ｐｇｐ）的表达进行检测，并对该单抗的特异性、检测结果与临床符合率以及预后的准确性进行评估。方法：应用免疫组化法检测了４７ 例实体瘤标本，应用药敏实验检测１５ 例儿童恶性肿瘤；应用间接免疫荧光法、ＲＴ－ ＰＣＲ 法和药敏实验检测了１０１ 例急性白血病（ＡＬ） 患者；用医学统计软件分析数据。结果：１） 在４７ 例实体瘤标本中，儿童恶性肿瘤中多药耐药阳性（ ＭＤＲ＋） 表达率较高（８６７ ％） ，乳腺癌淋巴结转移灶中ＭＤＲ＋ 表达率为６６７％ ，显著高于乳腺癌原发灶的３００ ％ （ Ｐ＜ ００１） 。２） 在１０１ 例急性白血病（ＡＬ） 患者中，难治和复发组的ＭＤＲ＋ 表达率（５２９ ％ ）显著高于初诊组（１９２ ％ ）（ Ｐ＜ ００１）。３） 单抗ＰＨＭＡ０２ 的检测结果与国外同型单抗ＪＳＢ－ １ 的平行检测结果呈正的直线相关（ Ｐ＜００５） ，与ＲＴ－ ＰＣＲ 的检测结果具有相关性（Ｐ＜ ００１） ；部分标本的药敏实验结果与单抗ＰＨＭＡ０２ 的检测结果基本一致。结论：１） 单抗ＰＨＭＡ０２ 的检测结果与临床有较好的符合率，可在临床上应用。２）Ｐｇｐ 在成人肺癌和乳腺癌中均有一?

OBJECTIVE: To detect the expression of P-glycoprotein (Pgp) in 148 cancer patients using monoclonal antibody PHMA02, and to evaluate the specificity, detection results, clinical coincidence rate, and prognosis of the monoclonal antibody. Methods: 47 cases of solid tumor specimens were detected by immunohistochemical method. 15 cases of childhood malignancy were detected by drug susceptibility test; 101 cases of acute leukemia (AL) patients were detected by indirect immunofluorescence, RT-PCR and drug susceptibility testing. Use medical statistics software to analyze the data. Results: 1) In 47 solid tumor specimens, the rate of MDR+ expression in children with malignant tumors was high (86.7%), and the rate of MDR+ expression in breast cancer with lymph node metastases was 66.7%. Significantly higher than 30.0% of primary breast cancer (P < 0. 01). 2) Among the 101 patients with acute leukemia (AL), the MDR+ expression rate in the refractory and relapsed group (52.9%) was significantly higher than that in the newly diagnosed group (19.5%) (P < 0.01). 3) The detection result of monoclonal antibody PHMA02 was positively correlated with the parallel detection result of foreign monoclonal antibody JSB-1 (P<005), and correlated with the RT-PCR test results (P<001); The susceptibility test results of some specimens were basically consistent with the detection results of monoclonal antibody PHMA02. Conclusions: 1) The detection results of monophasic PHMA02 have a good coincidence with the clinical and can be applied in clinical practice. 2) Is there a single Pgp in adult lung cancer and breast cancer?